TELK Share Price

Open 5.10 Change Price %
High 5.50 1 Day 0.00 0.00
Low 5.10 1 Week 0.00 0.00
Close 5.50 1 Month 0.00 0.00
Volume 841 1 Year 0.00 0.00
52 Week High 117.42
52 Week Low 80.46
TELK Important Levels
Resistance 2 5.87
Resistance 1 5.72
Pivot 5.37
Support 1 5.28
Support 2 5.13
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Telik, Inc. (NASDAQ: TELK)

TELK Technical Analysis 5
As on 9th Oct 2014 TELK Share Price closed @ 5.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.34 & Strong Buy for SHORT-TERM with Stoploss of 1.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
TELK Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TELK Other Details
Segment EQ
Market Capital 3358708.75
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.telik.com
TELK Address
TELK
2100 Geng Road
Suite 102
Palo Alto, CA 94303
United States
Phone: 650-845-7700
Fax: 650-845-7800
TELK Latest News
MabVax Therapeutics Files Investigational New Drug Application for Novel ...   PR Newswire (press release)   - 09th Jan 17
MabVax Therapeutics Expands Phase I Clinical Trial Investigation for Patients ...   PR Newswire (press release)   - 05th Dec 16
MabVax Therapeutics Reports Interim Safety and Imaging Results from Phase I ...   PR Newswire (press release)   - 14th Nov 16
MabVax Therapeutics HuMab-5B1 Based Diagnostic Imaging and Radioimmunotherapy ...   PR Newswire (press release)   - 26th Sep 16
MabVax Therapeutics to Present at the 18th Annual Rodman & Renshaw Global ...   PR Newswire (press release)   - 31st Aug 16
MabVax Therapeutics Announces Uplisting to The Nasdaq Capital Market and $8 ...   PR Newswire (press release)   - 17th Aug 16
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer   PR Newswire (press release)   - 15th Apr 16
News MabVax Therapeutics Holdings Inc.MBVX   Wall Street Journal   - 12th Oct 14
MabVax Therapeutics Receives Stockholder Approval for Name Change and Reverse ...   PR Newswire (press release)   - 09th Sep 14
Telik and MabVax Therapeutics Announce Definitive Merger Agreement   PR Newswire (press release)   - 13th May 14
Interactive Technical Analysis Chart Telik, Inc. ( TELK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Telik, Inc.
TELK Business Profile
Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In June 2011, the Company initiated a Phase II clinical trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. As of December 31, 2011, Telik had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphom and multiple myeloma.